Real World Efficacy of Pembrolizumab of as a 1st Line Treatment in Metastatic Non-Small Cell Lung Cancer with PD-L1 High Expression

被引:0
|
作者
Kasahara, K. [1 ]
Sone, T. [1 ]
Nishi, K. [2 ]
Shibata, K. [3 ]
Araya, T. [4 ]
Shirasaki, H. [5 ]
Yoneda, T. [6 ]
Kase, K. [7 ]
Nishikawa, S. [1 ]
Kimura, H. [1 ]
Tambo, Y. [1 ]
机构
[1] Kanazawa Univ, Resp Med, Kanazawa, Ishikawa, Japan
[2] Ishikawa Prefectural Cent Hosp, Resp Med, Kanazawa, Ishikawa, Japan
[3] Kouseiren Takaoka Hosp, Med Oncol, Takaoka, Toyama, Japan
[4] Natl Hosp Org Kanazawa Med Ctr, Resp Med, Kanazawa, Ishikawa, Japan
[5] Fukui Ken Saiseikai Hosp, Resp Med, Fukui, Japan
[6] Komatsu Municipal Hosp, Resp Med, Komatsu, Japan
[7] Keiju Med Ctr, Resp Med, Nanao, Japan
关键词
Pembrolizumab; 1st line treatment; PD-L1 high expression;
D O I
10.1016/j.jtho.2019.08.953
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P1.04-50
引用
收藏
页码:S460 / S460
页数:1
相关论文
共 50 条
  • [21] Efficacy and safety of the PD-1/PD-L1 in metastasic non-small cell lung cancer (NSCLC)
    Gonzalez-Velez, Abel
    Pino-Villareal, Luis E.
    Barrera-Barinas, Alexander
    Castillo-Niuman, Andrea
    Tolosa-Perez, Erica N.
    Castelblanco, Diana, I
    Pinzon-Florez, Carlos E.
    Yomayusa, Nancy
    GACETA MEXICANA DE ONCOLOGIA, 2021, 20 (03): : 111 - 123
  • [22] Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer
    Dori, Shani Ben
    Aizic, Asaf
    Sabo, Edmond
    Hershkovitz, Dov
    LUNG CANCER, 2020, 147 : 91 - 98
  • [23] Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression
    Ishizuka, Shiho
    Sakata, Shinya
    Yoshida, Chieko
    Takaki, Akira
    Saeki, Sho
    Nakamura, Kazuyoshi
    Fujii, Kazuhiko
    RESPIRATORY INVESTIGATION, 2018, 56 (04) : 361 - 364
  • [24] Real-world data on efficacy and safety of pembrolizumab in the first-line treatment of metastatic lung cancer in patients with PD-L1 expression >0% - a single center experience
    Cvijic, T.
    Canjko, I.
    Tomas, I.
    Kralik, K.
    Peric, L.
    Kotromanovic, D.
    Dupan, Z. Krivdic
    Peic, A. Kovac
    Mimica, S.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (19) : 9213 - 9225
  • [25] PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations
    Scheel, Andreas H.
    Ansen, Sascha
    Schultheis, Anne M.
    Scheffler, Matthias
    Fischer, Rieke N.
    Michels, Sebastian
    Hellmich, Martin
    George, Julie
    Zander, Thomas
    Brockmann, Michael
    Stoelben, Erich
    Groen, Harry
    Timens, Wim
    Perner, Sven
    von Bergwelt-Baildon, Michael
    Buettner, Reinhard
    Wolf, Juergen
    ONCOIMMUNOLOGY, 2016, 5 (05):
  • [26] Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ≥50%
    Metro, Giulio
    Banna, Giuseppe Luigi
    Signorelli, Diego
    Gili, Alessio
    Galetta, Domenico
    Galli, Giulia
    Economopoulou, Panagiota
    Roila, Fausto
    Friedlaender, Alex
    Camerini, Andrea
    Christopoulou, Athina
    Cantale, Ornella
    De Toma, Alessandro
    Pizzutilo, Pamela
    Jimenez, Beatriz
    Collazo-Lorduy, Ana
    Calles, Antonio
    Baxevanos, Panagiotis
    Linardou, Helena
    Kosmidis, Paris
    Giannarelli, Diana
    Mountzios, Giannis
    Addeo, Alfredo
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (09) : 299 - 306
  • [27] Current PD-L1 immunohistochemistry for non-small cell lung cancer
    Scheel, Andreas H.
    Schaefer, Stephan C.
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1217 - 1219
  • [28] PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer
    Shankar, Bairavi
    Naidoo, Jarushka
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S4034 - S4037
  • [29] Targeting the PD-1/PD-L1 axis in non-small cell lung cancer
    Kumar, Rajiv
    Collins, Dearbhaile
    Dolly, Saoirse
    McDonald, Fiona
    O'Brien, Mary E. R.
    Yap, Timothy A.
    CURRENT PROBLEMS IN CANCER, 2017, 41 (02) : 111 - 124
  • [30] Characterizing the Shifting Real-World Treatment Landscape by PD-L1 Testing Status and Expression Level in Advanced Non-Small Cell Lung Cancer
    Ge, Wenzhen
    Wu, Ning
    Quek, Ruben G. W.
    Liu, Jinjie
    Pouliot, Jean-Francois
    Dietz, Hilary
    Jalbert, Jessica J.
    Harnett, James
    Antonia, Scott J.
    ADVANCES IN THERAPY, 2022, 39 (10) : 4645 - 4662